The stock of Cogentix Medical Inc (NASDAQ:CGNT) is a huge mover today! About 201,548 shares traded hands or 24.34% up from the average. Cogentix Medical Inc (NASDAQ:CGNT) has risen 83.81% since April 26, 2016 and is uptrending. It has outperformed by 78.55% the S&P500.
The move comes after 5 months positive chart setup for the $112.82M company. It was reported on Nov, 29 by Barchart.com. We have $2.31 PT which if reached, will make NASDAQ:CGNT worth $7.90 million more.
Cogentix Medical Inc (NASDAQ:CGNT) Ratings Coverage
Out of 2 analysts covering Cogentix Medical (NASDAQ:CGNT), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Cogentix Medical has been the topic of 3 analyst reports since November 5, 2015 according to StockzIntelligence Inc. The company was upgraded on Thursday, November 5 by Roth Capital. Roth Capital downgraded it to “Neutral” rating and $1.15 target price in Friday, May 6 report. TH Capital upgraded Cogentix Medical Inc (NASDAQ:CGNT) on Thursday, November 5 to “Buy” rating.
According to Zacks Investment Research, “Cogentix Medical, Inc. is a medical device company which designs, develops, manufactures and markets proprietary technologies serving the urology market. The company’s primary product consists of Urgent(R) PC Neuromodulation System and EndoSheath System. It operates primarily in Orangeburg, New York, The Netherlands and the United Kingdom. Cogentix Medical, Inc., formerly known as Vision-Sciences Inc., is headquartered in Orangeburg, New York.”
More recent Cogentix Medical Inc (NASDAQ:CGNT) news were published by: Prnewswire.com which released: “Cogentix Medical Enters Into Definitive Agreement For $25 Million Equity …” on September 07, 2016. Also Prnewswire.com published the news titled: “Cogentix Medical Shareholders Approve $25 Million Equity Investment” on November 03, 2016. Prnewswire.com‘s news article titled: “Cogentix Medical Announces Settlement Agreement in Connection with Proxy …” with publication date: May 24, 2016 was also an interesting one.
CGNT Company Profile
Cogentix Medical, Inc., incorporated on October 19, 1987, is a global medical device company. The Firm designs, develops, makes and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Firm also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office treatment of overactive bladder (OAB). The Firm also offers Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence that is primarily due to intrinsic sphincter deficiency. The PrimeSight flexible endoscopes are used in conjunction with the sterile, single-use microbial barrier known as the EndoSheath Protective Barrier. The PrimeSight endoscopy line also includes rigid endoscopes and portable peripherals, such as the video system and stroboscopy unit.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.